Abstract
Epithelial to mesenchymal transition (EMT) represents a phenotypic change that occurs in epithelial tumors that is required for cancer cells to acquire metastatic potential. This phenotypic transition occurs by downregulating the epithelial-specific markers such as E-cadherin and activation of the mesenchymal markers represented by fibronectin, vimentin, and N-cadherin. This process is associated with morphologic alterations of the tumor cells, as they are losing the intercellular junctions, lose cellular polarity, and undergo a cytoskeletal architectural reorganization which results in changes of the cell shape. EMT is a dynamic process that occurs in both directions; therefore cells that underwent a mesenchymal transition have the ability to change their phenotype in an epithelial one by reactivating cellular pathways during the mesenchymal to epithelial transition (MET). This two-way process is essential in the process of metastasis, surviving in the blood or lymphatic circulation and once seeded in the secondary site to be able to adapt and proliferate in the new environmental conditions. EMT is generally regarded as a cellular process that occurs in the late phases of tumorigenesis once the primary tumor is well established. New studies that investigated the process of EMT in lung cancer revealed that EMT actually occurs in the initial stages of tumor development. Several studies indicate the identification of circulating tumor cells, a hallmark of the EMT process, as early as in situ stage of lung adenocarcinoma. Therefore, understanding the mechanisms that trigger the EMT process by decoding the complex network of noncoding RNAs that initiate and regulate this phenotype transition can uncover new biomarkers, cellular vulnerabilities, and therapeutic pathways.
This is a preview of subscription content, log in via an institution to check access.
References
Ancel J et al (2022) Clinical impact of the epithelial-mesenchymal transition in lung cancer as a biomarker assisting in therapeutic decisions. Cells Tissues Organs 211(2):91–109. https://doi.org/10.1159/000510103
Arumugam T et al (2009) Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 69(14):5820–5828. https://doi.org/10.1158/0008-5472.CAN-08-2819
Ashrafizadeh M et al (2021) Crosstalk of long non-coding RNAs and EMT: searching the missing pieces of an incomplete puzzle for lung cancer therapy. Curr Cancer Drug Targets 21(8):640–665. https://doi.org/10.2174/1568009621666210203110305
Bhangu A et al (2012) Epithelial mesenchymal transition in colorectal cancer: seminal role in promoting disease progression and resistance to neoadjuvant therapy. Surg Oncol 21(4):316–323. https://doi.org/10.1016/J.SURONC.2012.08.003
Brabletz T et al (2018) EMT in cancer. Nat Rev Cancer 18(2):128–134. https://doi.org/10.1038/NRC.2017.118
Bray F et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 68(6):394–424. https://doi.org/10.3322/CAAC.21492
Bunn PA et al (2016) Small cell lung cancer: can recent advances in biology and molecular biology be translated into improved outcomes? J Thorac Oncol 11(4):453–474. https://doi.org/10.1016/J.JTHO.2016.01.012
Burrell RA et al (2013) The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501(7467):338–345. https://doi.org/10.1038/NATURE12625
Cai ZG et al (2018) Down-regulation of miR-26 plays essential roles in TGFβ-induced EMT. Cell Biol Int 44(1):352. https://doi.org/10.1002/CBIN.11029
Cavallari I et al (2021) The miR-200 family of microRNAs: fine tuners of epithelial-mesenchymal transition and circulating cancer biomarkers. Cancers (Basel) 13(23). https://doi.org/10.3390/CANCERS13235874
Ceppi P et al (2010) Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res 8(9):1207–1216. https://doi.org/10.1158/1541-7786.MCR-10-0052
Chen C et al (2022) Predictive value of TCR Vβ-Jβ profile for adjuvant gefitinib in EGFR mutant NSCLC from ADJUVANT-CTONG 1104 trial. JCI Insight 7(1). https://doi.org/10.1172/JCI.INSIGHT.152631
De Las Rivas J et al (2021) Cancer drug resistance induced by EMT: novel therapeutic strategies. Arch Toxicol 95(7):2279–2297. https://doi.org/10.1007/S00204-021-03063-7
Deng B et al (2011) Breast cancer anti-estrogen resistance protein 1 (BCAR1/p130cas) in pulmonary disease tissue and serum. Mol Diagn Ther 15(1):31–40. https://doi.org/10.1007/BF03257191
Dong N et al (2017) Role of epigenetics in lung cancer heterogeneity and clinical implication. Semin Cell Dev Biol 64:18–25. https://doi.org/10.1016/J.SEMCDB.2016.08.029
Emprou C et al (2018) SNAI2 and TWIST1 in lymph node progression in early stages of NSCLC patients. Cancer Med 7(7):3278. https://doi.org/10.1002/CAM4.1545
Fan CC et al (2020) EFHD2 contributes to non-small cell lung cancer cisplatin resistance by the activation of NOX4-ROS-ABCC1 axis. Redox Biol 34:101571. https://doi.org/10.1016/J.REDOX.2020.101571
Feng YL et al (2020) Small molecule inhibitors of epithelial-mesenchymal transition for the treatment of cancer and fibrosis. Med Res Rev 40(1):54–78. https://doi.org/10.1002/MED.21596
Francou A, Anderson KV (2020) The epithelial-to-mesenchymal transition (EMT) in development and cancer. Annu Rev Cancer Biol 4:197–220. https://doi.org/10.1146/ANNUREV-CANCERBIO-030518-055425
Gauthier-Rouvière C et al (2020) Flotillin membrane domains in cancer. Cancer Metastasis Rev 39(2):361–374. https://doi.org/10.1007/S10555-020-09873-Y
Gerber DE, Oxnard GR, Govindan R (2015) ALCHEMIST: bringing genomic discovery and targeted therapies to early-stage lung cancer. Clin Pharmacol Ther 97(5):447–450. https://doi.org/10.1002/CPT.91
Hao Y et al (2017) Long noncoding RNA LINC01186, regulated by TGF-β/SMAD3, inhibits migration and invasion through epithelial-mesenchymal-transition in lung cancer. Gene 608:1–12. https://doi.org/10.1016/J.GENE.2017.01.023
Hao Y, Baker D, Ten Dijke P (2019) TGF-β-mediated epithelial-mesenchymal transition and cancer metastasis. Int J Mol Sci 20(11). https://doi.org/10.3390/IJMS20112767
He W et al (2015) Astrocyte elevated gene-1(AEG-1) induces epithelial-mesenchymal transition in lung cancer through activating Wnt/β-catenin signaling. BMC Cancer 15(1):107. https://doi.org/10.1186/S12885-015-1124-1
He R, Zhang F, hu and Shen, N. (2017) LncRNA FEZF1-AS1 enhances epithelial-mesenchymal transition (EMT) through suppressing E-cadherin and regulating WNT pathway in non-small cell lung cancer (NSCLC). Biomed Pharmacother 95:331–338. https://doi.org/10.1016/J.BIOPHA.2017.08.057
Heidemann F et al (2014) Selectins mediate small cell lung cancer systemic metastasis. PLoS One 9(4):e92327. https://doi.org/10.1371/JOURNAL.PONE.0092327
Huang W et al (2020) Mechanism of epithelial-mesenchymal transition inhibited by miR-203 in non-small cell lung cancer. Oncol Rep 43(2):437–446. https://doi.org/10.3892/OR.2019.7433
Huang P et al (2021) Revisiting lung cancer metastasis: insight from the functions of long non-coding RNAs. Technol Cancer Res Treat 20:153303382110384. https://doi.org/10.1177/15330338211038488
Huh YH et al (2015) Swiprosin-1 stimulates cancer invasion and metastasis by increasing the rho family of GTPase signaling. Oncotarget 6(15):13060–13071. https://doi.org/10.18632/ONCOTARGET.3637
Ilie M et al (2014) “Sentinel” circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease. PLoS One 9(10):e111597. https://doi.org/10.1371/JOURNAL.PONE.0111597
Janda E et al (2006) Raf plus TGFbeta-dependent EMT is initiated by endocytosis and lysosomal degradation of E-cadherin. Oncogene 25(54):7117–7130. https://doi.org/10.1038/SJ.ONC.1209701
Jia X et al (2016) Upregulation of LncRNA-HIT promotes migration and invasion of non-small cell lung cancer cells by association with ZEB1. Cancer Med 5(12):3555–3563. https://doi.org/10.1002/CAM4.948
Jia Z et al (2018) miR-126 suppresses epithelial-to-mesenchymal transition and metastasis by targeting PI3K/AKT/snail signaling of lung cancer cells. Oncol Lett 15(5):7369. https://doi.org/10.3892/OL.2018.8207
Jin XR et al (2017) Circulating tumor cells in early stage lung adenocarcinoma: a case series report and literature review. Oncotarget 8(14):23130. https://doi.org/10.18632/ONCOTARGET.15506
Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119(6):1420–1428. https://doi.org/10.1172/JCI39104
Kang Y, Massagué J (2004) Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118(3):277–279. https://doi.org/10.1016/j.cell.2004.07.011
Karacosta LG et al (2019) Mapping lung cancer epithelial-mesenchymal transition states and trajectories with single-cell resolution. Nat Commun 10(1):5587. https://doi.org/10.1038/S41467-019-13441-6
Klauzinska M et al (2014) The multifaceted role of the embryonic gene Cripto-1 in cancer, stem cells and epithelial-mesenchymal transition. Semin Cancer Biol 29(C):51–58. https://doi.org/10.1016/J.SEMCANCER.2014.08.003
Krebs AM et al (2017) The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat Cell Biol 19(5):518–529. https://doi.org/10.1038/NCB3513
Krohn A et al (2014) Tumor cell heterogeneity in small cell lung cancer (SCLC): phenotypical and functional differences associated with epithelial-mesenchymal transition (EMT) and DNA methylation changes. PLoS One 9(6):e100249. https://doi.org/10.1371/JOURNAL.PONE.0100249
Lai X et al (2020) Epithelial-mesenchymal transition and metabolic switching in cancer: lessons from somatic cell reprogramming. Front Cell Dev Biol 8. https://doi.org/10.3389/FCELL.2020.00760
Lamouille S, Xu J, Derynck R (2014) Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15(3):178–196. https://doi.org/10.1038/NRM3758
Larsen JE et al (2016) ZEB1 drives epithelial-to-mesenchymal transition in lung cancer. J Clin Invest 126(9):3219–3235. https://doi.org/10.1172/JCI76725
Li J et al (2014) miRNA-200c inhibits invasion and metastasis of human non-small cell lung cancer by directly targeting ubiquitin specific peptidase 25. Mol Cancer 13(1). https://doi.org/10.1186/1476-4598-13-166
Li J et al (2015) MicroRNA-19 triggers epithelial-mesenchymal transition of lung cancer cells accompanied by growth inhibition. Lab Investig 95(9):1056–1070. https://doi.org/10.1038/LABINVEST.2015.76
Li J et al (2016) LncRNA MALAT1 exerts oncogenic functions in lung adenocarcinoma by targeting miR-204. Am J Cancer Res 6(5):1099
Li Z et al (2018) Lnc-SNHG1 may promote the progression of non-small cell lung cancer by acting as a sponge of miR-497. Biochem Biophys Res Commun 506(3):632–640. https://doi.org/10.1016/J.BBRC.2018.10.086
Li T et al (2019) MiR-1-3p inhibits lung adenocarcinoma cell tumorigenesis via targeting protein regulator of cytokinesis 1. Front Oncol 9(Mar). https://doi.org/10.3389/FONC.2019.00120
Li L et al (2020) A TGF-β-MTA1-SOX4-EZH2 signaling axis drives epithelial-mesenchymal transition in tumor metastasis. Oncogene 39(10):2125–2139. https://doi.org/10.1038/S41388-019-1132-8
Lin J et al (2018) MicroRNA-155-5p suppresses the migration and invasion of lung adenocarcinoma A549 cells by targeting Smad 2. Oncol Lett 16(2):2444–2452. https://doi.org/10.3892/OL.2018.8889
Liu B et al (2016) Long noncoding RNA-LET suppresses tumor growth and EMT in lung adenocarcinoma. Biomed Res Int 2016:1. https://doi.org/10.1155/2016/4693471
Lu W et al (2017) Long non-coding RNA linc00673 regulated non-small cell lung cancer proliferation, migration, invasion and epithelial mesenchymal transition by sponging miR-150-5p. Mol Cancer 16(1):118. https://doi.org/10.1186/S12943-017-0685-9
Marjanovic ND et al (2020) Emergence of a high-plasticity cell state during lung cancer evolution. Cancer Cell 38(2):229–246.e13. https://doi.org/10.1016/J.CCELL.2020.06.012
Marusyk A et al (2014) Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature 514(7520):54–58. https://doi.org/10.1038/NATURE13556
Matsubara T et al (2019) Clinical and prognostic significance of the epithelial-mesenchymal transition in stage IA lung adenocarcinoma: a propensity score-matched analysis. Clin Lung Cancer 20(4):e504–e513. https://doi.org/10.1016/J.CLLC.2019.04.006
Naz F et al (2021) Cancer stem cells: a major culprit of intra-tumor heterogeneity. Am J Cancer Res 11(12):5782
Paoli P, Giannoni E, Chiarugi P (2013) Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta 12:3481–3498. https://doi.org/10.1016/J.BBAMCR.2013.06.026
Park KS et al (2018) High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer. Lung Cancer 116:38–45. https://doi.org/10.1016/J.LUNGCAN.2017.12.010
Parker DA, Parker ES (1980) Status and status inconsistency of parents on alcohol consumption of teenage children. Int J Addict 15(8):1233–1239. https://doi.org/10.3109/10826088009040093
Pirlog R, Cismaru A et al (2021a) Field cancerization in NSCLC: a new perspective on MicroRNAs in macrophage polarization. Int J Mol Sci 22(2):1–17. https://doi.org/10.3390/IJMS22020746
Pirlog R, Drula R et al (2021b) The roles of the colon cancer associated transcript 2 (CCAT2) long non-coding RNA in cancer: a comprehensive characterization of the tumorigenic and molecular functions. Int J Mol Sci 22(22). https://doi.org/10.3390/IJMS222212491
Pirlog R, Chiroi P et al (2022a) Cellular and molecular profiling of tumor microenvironment and early-stage lung cancer. Int J Mol Sci 23(10). https://doi.org/10.3390/IJMS23105346
Pirlog R, Piton N et al (2022b) Morphological and molecular characterization of KRAS G12C-mutated lung adenocarcinomas. Cancers (Basel) 14(4). https://doi.org/10.3390/CANCERS14041030
Planchard D et al (2018) Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 29:192–237. https://doi.org/10.1093/annonc/mdy275
Puisieux A, Brabletz T, Caramel J (2014) Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol 16(6):488–494. https://doi.org/10.1038/NCB2976
Qian H et al (2018) The lncRNA MIR4435-2HG promotes lung cancer progression by activating β-catenin signalling. J Mol Med (Berl) 96(8):753–764. https://doi.org/10.1007/S00109-018-1654-5
Qu R, Chen X, Zhang C (2018) LncRNA ZEB1-AS1/miR-409-3p/ZEB1 feedback loop is involved in the progression of non-small cell lung cancer. Biochem Biophys Res Commun 507(1–4):450–456. https://doi.org/10.1016/J.BBRC.2018.11.059
Raimondi C et al (2017) PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: a molecular shield to evade immune system ? Onco Targets Ther 6(12):e1315488. https://doi.org/10.1080/2162402X.2017.1315488
Ribatti D, Tamma R, Annese T (2020) Epithelial-mesenchymal transition in cancer: a historical overview. Trans Oncol 13(6):100773. https://doi.org/10.1016/J.TRANON.2020.100773
Roche J et al (2013) Global decrease of histone H3K27 acetylation in ZEB1-induced epithelial to mesenchymal transition in lung cancer cells. Cancers (Basel) 5(2):334–356. https://doi.org/10.3390/CANCERS5020334
Salomon DS, Bianco C, De Santis M (1999) Cripto: a novel epidermal growth factor (EGF)-related peptide in mammary gland development and neoplasia. BioEssays 21(1):61–70. https://doi.org/10.1002/(SICI)1521-1878(199901)21:1<61::AID-BIES8>3.0.CO;2-H
Schegoleva AA et al (2021) Prognosis of different types of non-small cell lung cancer progression: current state and perspectives. Cell Physiol Biochem 55(S2):29–48. https://doi.org/10.33594/000000340
Shook D, Keller R (2003) Mechanisms, mechanics and function of epithelial-mesenchymal transitions in early development. Mech Dev 120(11):1351–1383. https://doi.org/10.1016/j.mod.2003.06.005
Song J et al (2019) Epithelial-mesenchymal transition markers screened in a cell-based model and validated in lung adenocarcinoma. BMC Cancer 19(1):680. https://doi.org/10.1186/S12885-019-5885-9
Song K et al (2020) Members of the miR-30 family inhibit the epithelial-to-mesenchymal transition of non-small-cell lung cancer cells by suppressing XB130 expression levels. Oncol Lett 20(4):68. https://doi.org/10.3892/OL.2020.11929
Sun M et al (2014a) Downregulation of BRAF activated non-coding RNA is associated with poor prognosis for non-small cell lung cancer and promotes metastasis by affecting epithelial-mesenchymal transition. Mol Cancer 13(1). https://doi.org/10.1186/1476-4598-13-68
Sun M et al (2014b) EZH2-mediated epigenetic suppression of long noncoding RNA SPRY4-IT1 promotes NSCLC cell proliferation and metastasis by affecting the epithelial-mesenchymal transition. Cell Death Dis 5(6):e1298. https://doi.org/10.1038/CDDIS.2014.256
Tan AC, Tan DSW (2022) Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol 40(6):611–625. https://doi.org/10.1200/JCO.21.01626
Terashima M et al (2017) MEG3 long noncoding RNA contributes to the epigenetic regulation of epithelial-mesenchymal transition in lung cancer cell lines. J Biol Chem 292(1):82–99. https://doi.org/10.1074/JBC.M116.750950
Thai AA et al (2021) Lung cancer. Lancet 398(10299):535–554. https://doi.org/10.1016/S0140-6736(21)00312-3
Thiery JP et al (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5):871–890. https://doi.org/10.1016/J.CELL.2009.11.007
Tian J et al (2016) MicroRNA-130b promotes lung cancer progression via PPARγ/VEGF-A/BCL-2-mediated suppression of apoptosis. J Exp Clin Cancer Res 35(1):105. https://doi.org/10.1186/S13046-016-0382-3
Tsai JH, Yang J (2013) Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev 27(20):2192–2206. https://doi.org/10.1101/GAD.225334.113
Vasan N, Baselga J, Hyman DM (2019) A view on drug resistance in cancer. Nature 575(7782):299–309. https://doi.org/10.1038/S41586-019-1730-1
Wang H et al (2017a) TGF-β1-induced epithelial-mesenchymal transition in lung cancer cells involves upregulation of miR-9 and downregulation of its target, E-cadherin. Cell Mol Biol Lett 22(1):22. https://doi.org/10.1186/S11658-017-0053-1
Wang T et al (2017b) Transcription factor E2F1 promotes EMT by regulating ZEB2 in small cell lung cancer. BMC Cancer 17(1):719. https://doi.org/10.1186/S12885-017-3701-Y
Williams MJ et al (2016) Identification of neutral tumor evolution across cancer types. Nat Genet 48(3):238–244. https://doi.org/10.1038/NG.3489
Willis BC, Borok Z (2007) TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol 293(3):L525. https://doi.org/10.1152/AJPLUNG.00163.2007
Wu YL et al (2018) ADAURA: phase III, double-blind, randomized study of Osimertinib versus placebo in EGFR mutation-positive early-stage NSCLC after complete surgical resection. Clin Lung Cancer 19(4):e533–e536. https://doi.org/10.1016/J.CLLC.2018.04.004
Wu SG et al (2019) MicroRNA in lung cancer metastasis. Cancers 11(2):265. https://doi.org/10.3390/CANCERS11020265
Wu P et al (2020) Emerging role of tumor-related functional peptides encoded by lncRNA and circRNA. Mol Cancer 19(1):22. https://doi.org/10.1186/S12943-020-1147-3
Xiao D, He J (2010) Epithelial mesenchymal transition and lung cancer. J Thorac Dis 2(3):154–159. https://doi.org/10.3978/J.ISSN.2072-1439.2010.02.03.7
Xu W et al (2015) MicroRNA-191, by promoting the EMT and increasing CSC-like properties, is involved in neoplastic and metastatic properties of transformed human bronchial epithelial cells. Mol Carcinog 54(Suppl 1):E148–E161. https://doi.org/10.1002/MC.22221
Xu Q et al (2016) Long non-coding RNA regulation of epithelial-mesenchymal transition in cancer metastasis. Cell Death Dis 7(6):e2254. https://doi.org/10.1038/CDDIS.2016.149
Xu R et al (2021) MicroRNA-181a promotes epithelial-mesenchymal transition in esophageal squamous cell carcinoma via the TGF-β/Smad pathway. Mol Med Rep 23(5). https://doi.org/10.3892/MMR.2021.11955
Yang MH et al (2008) Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 10(3):295–305. https://doi.org/10.1038/NCB1691
Yang J et al (2020) Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 21(6):341–352. https://doi.org/10.1038/S41580-020-0237-9
Yochum ZA et al (2019) Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer. Oncogene 38(5):656–670. https://doi.org/10.1038/S41388-018-0482-Y
Yuan X et al (2014) Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application. J Hematol Oncol 7(1):87. https://doi.org/10.1186/S13045-014-0087-Z
Zeng Z et al (2020) Distinct expression and prognostic value of members of SMAD family in non-small cell lung cancer. Medicine (Baltimore) 99(10):e19451. https://doi.org/10.1097/MD.0000000000019451
Zhang N, Wei X, Xu L (2013) miR-150 promotes the proliferation of lung cancer cells by targeting P53. FEBS Lett 587(15):2346–2351. https://doi.org/10.1016/J.FEBSLET.2013.05.059
Zhang K et al (2017) MiR-22 inhibits lung cancer cell EMT and invasion through targeting snail. Eur Rev Med Pharmacol Sci 21(16):3598–3604. https://doi.org/10.26355/EURREV_201708_13271
Zhang C et al (2018) TGF-β/SMAD4-regulated LncRNA-LINP1 inhibits epithelial-mesenchymal transition in lung cancer. Int J Biol Sci 14(12):1715–1723. https://doi.org/10.7150/IJBS.27197
Zhao L et al (2018) Flotillin1 promotes EMT of human small cell lung cancer via TGF-β signaling pathway. Cancer Biol Med 15(4):400–414. https://doi.org/10.20892/J.ISSN.2095-3941.2018.0053
Zhou B et al (2018) Effect of miR-21 on apoptosis in lung cancer cell through inhibiting the PI3K/Akt/NF-κB signaling pathway in vitro and in vivo. Cell Physiol Biochem 46(3):999–1008. https://doi.org/10.1159/000488831
Zhu X et al (2017) microRNA-664 enhances proliferation, migration and invasion of lung cancer cells. Exp Ther Med 13(6):3555. https://doi.org/10.3892/ETM.2017.4433
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Pirlog, R., Chiroi, P., Raduly, L., Nutu, A., Cismaru, A., Berindan-Neagoe, I. (2023). Epithelial to Mesenchymal Transition in Lung Cancer: When It Starts?. In: Interdisciplinary Cancer Research. Springer, Cham. https://doi.org/10.1007/16833_2023_137
Download citation
DOI: https://doi.org/10.1007/16833_2023_137
Published:
Publisher Name: Springer, Cham